The global recombinant peptide market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Peptides are extremely active and highly specific drug substances. They are used in an extensive range of therapeutic areas on account of the diversity of their biological functions. Peptides are gradually entering drug development pathways as potential active pharmaceutical ingredients (API) on the back of their hefty chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity. The market growth is expected to be driven by the surging use of peptides in pharmaceutical drugs, growth in research activities and availability of funding for R&D, and the development of advanced automated peptide synthesizers across the globe. 

Peptides are extensively used in three prominent therapeutics areas namely oncology, diabetes, and obesity. Moreover, the demand for peptides is soaring for the treatment of cardiovascular and neurodegenerative diseases, renal failure, and rare diseases. Further, the development of personalized medicines globally is expected to create ample opportunities for market growth in the near future. Interest in personalized treatment has been driven by the concept of tailored therapy with the best response and highest safety margin to ensure better patient care. Some key players operating in the market include Amgen Inc., Novartis International AG, and Biocon Ltd., among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Amgen Inc., Novartis International AG, and Biocon Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Recombinant Peptide Market Report by Segment

By Type 

• Glucagon
• Calcitonin
• Others

By Application

• Oncology
• Blood Disorders
• Infectious Diseases
• Autoimmune Diseases
• Others

Global Recombinant Peptide Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa